Login to Your Account

Karo Bio Stock Plunges, Safety Issues Scuttle Eprotirome Trial

By Cormac Sheridan
Staff Writer

Wednesday, February 15, 2012

Shares in Karo Bio AB plunged more than 66 percent Tuesday on news that the company was terminating a Phase III pivotal trial of its lead drug eprotirome, after a toxicology study in dogs indicated that long-term exposure could result in cartilage damage.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription